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Background. The first iteration of the EU Directive that controls the 1 deliberate release of GMOs into the environment was adopted in 1990, and 2 the first commercial planting of GM crops occurred in 1996 in the USA (or 3 1998 in the EU). Since then, the global cultivated area has risen to exceed 4 170 M ha and the majority of global production of soya and cotton is via GM 5 varieties [1] . Over this period, cultivation within the EU has been restricted to 6 ca 0.1M ha. Although the main barrier to release of GM food crops for 7 cultivation in the EU lies at the political level, the UK Advisory Committee on 8
Releases to the Environment (ACRE) has recently raised concerns both about 9 the regulatory approach adopted by the EU and the implementation of the 10 current current processes for carrying out Environmental Risk assessments 11 (ERA) process and about their future fitness for purpose (ACRE 12 http://www.*wp1-3). This article summarises these concerns and suggests a 13 way forward. 14 Addressing current challenges. These include the lack of precision with 15 which the concept of adverse effects (harm) is used within ERA and the 16 challenges of developing a proportionate approach to unanticipated effects 17 Adverse Effects. There is no consensus within the EU as to what constitutes an 18 adverse environmental effect. This has led to increasing data requirements and 19 to inappropriate recommendations for risk management options. The , and this 20 leads to difficulties asre illustrated by GM herbicide tolerant crops. These 21 systems allow farmers to practice efficient weed control to enhance crop 22 productivity, potentially at the expense of biodiversity that depends upon weeds 23 at the base of the food chain. This negative impact could be compensated for by 24
Comment [RSH1]:
Actually the example we give, with GMHT crops, is about absence of defined risk management because harm has not been defined. This more general statement is more relevant to GMIR crops. Monitoring and dDealing with the unexpected. In addition to assessing the risks 8 associated with the intended changes made to a GM crop, ERA must also 9 address the possibility that any identified unintended changes could cause 10 harm. In the absence of a plausible link between a characteristic of a GM crop 11 (and its use) and such harm, there is the potential for open-ended evidence-12 gathering that does not add value to the risk assessment. It is not possible 13 practical to test for ERA to identify unintended effects in advance by testing 14 every characteristic of a GM crop and its use under every conceivable scenario. 15
It is important therefore, that the EU adopts a proportionate approach that 16 makes optimal use of existing evidence. There is a significant 'weight of 17 evidence' available from the cultivation of GM crops outside of the EU as well as 18 from existing information requirements. Where this evidence indicates changes 19 to a GM crop, or its use ,are identified and potentially that can be linked to 20 adverse effects, the ERA should follow a structured and proportionate process 21 to characterise the risk to the environment. Where identified but unintended 22 changes cannot be plausibly linked to adverse effects, further data should not 23 be required. Finally, some countries, including those in the EU, require post-market 1 monitoring to detect any unanticipated adverse effects from the commercial 2 growing of GM crops. In this context, WhereIn terms of unintended effects, 3 cannot be defined nor linked to a GMO, ACRE supports the use of effective 4 questionnaires to detect significant changes aimed at users of the product but 5 is doubtful of the value of large-scale environmental monitoring to attribute 6 causality to the cultivation of GM crops 7 (http://www.defra.gov.uk/acre/files/pmem-final-report.pdf; ACRE http://* WP2). 8
Emerging Challenges For Process-based Regulation. The current EU 9
Directive lists techniques that can lead to the generation of GMOs and those 10 which are deemed not to. However, these lists are not exhaustive, which leads 11 to confusion in interpretation of the regulations as to whether the legislation 12 applies to novel organisms developed by techniques that were not envisaged 13 when the legislation was adopted in 1990. This approach to regulating 14 organisms based on how they were produced (so-called "process-based") was 15 adopted in 1990 and at this time, many of the techniques being used and 16 developed today were not envisaged. Consequently, it is not clear whether the 17 organisms produced by them are captured by the GMO legislation. This results 18 in regulatory uncertainty -a major block to innovation and to effective ERA. 19
Adoption of a process-based regulatory system dditionally, basing a regulatory 20 system on how organisms are produced has resulted in also results in 21 organisms with the same phenotype being dealt with differently (e.g. 22 phenotypically identical herbicide-tolerant plants produced by transgenesis or 23 traditional mutagenesis). This disparity may increase become more evident 24 depending on whether regulators consider organisms produced by a suite of 25
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And |I think this paragraph is needed.
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Comment from Louise about this section:
' ACRE has already been criticised for not understanding how the legislation works so it's important to get this right.
The original draft talks about a processbased approach then, at the end talks about whether the product occurs naturally without connecting the 2.. I've moved the text from the end to the front to make it clear that the definition has 2 parts and there are problems with both parts i.e. process -based bit only categorically deals with transgenics and the genotype element is nonsensical given what we now know about genomes.
I amended the text so that it wasn't so confusing and added the 'genotype' element in the last section.' capture the range of artificially induced alterations to an organism's genetic 1 material. Now that the extent of natural genetic and epigenetic variation is more 2 fully understood, identifying alterations that do not occur naturally is much more 3 challenging. Within an individual and between individuals of the same species, 4 the genetic material can exist in naturally altered forms whilst the phenotype 5 remains unchanged, through the effects of genetic redundancy between 6 multigene family members [4, 5] Equally, a single nucleotide change can result 7 in a significant phenotype change (ACRE http://www.wp3*). 8 9 Options for Change. A major reason for regulating organisms based on how 10 they were developed is to address the concern that the technologies may cause 11 unintended alterations to the organisms' genetic material that could not have 12 occurred naturally or through conventional breeding. Since the GMO legislation 13 was adopted in 1990 we have learned a great deal from genomic studies. We 14 now understand that this notion that genomes are relatively uniform and stable 15 entities is incorrect. Within an individual and between individuals of the same 16 species, the genetic material can exist in naturally altered forms whilst the 17 phenotype remains unchanged, through the effects of genetic redundancy 18 between multigene family members [4, 5] Equally, a single nucleotide change 19 can result in a significant phenotype change (ACRE http://www.wp3*). We have 20 also gained significant evidence from the widespread use of GMOs. From this 21
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we conclude thatWe propose that there is little scientific justification for a 22 regulatory system that is triggered by the process by which new organisms are 23 developed (i.e. recombinant DNA technology) rather than by their novelty or 24 potential for harm (i.e. their phenotype).
